These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21883022)

  • 1. Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.
    Ryan JL; Krishnan S; Movsas B; Coleman CN; Vikram B; Yoo SS
    Radiat Res; 2011 Nov; 176(5):688-91. PubMed ID: 21883022
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
    Movsas B; Vikram B; Hauer-Jensen M; Moulder JE; Basch E; Brown SL; Kachnic LA; Dicker AP; Coleman CN; Okunieff P
    Clin Cancer Res; 2011 Jan; 17(2):222-8. PubMed ID: 21047979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic approaches to radiation protection.
    Brizel DM
    J Clin Oncol; 2007 Sep; 25(26):4084-9. PubMed ID: 17827457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioprotectors and mitigators of radiation-induced normal tissue injury.
    Citrin D; Cotrim AP; Hyodo F; Baum BJ; Krishna MC; Mitchell JB
    Oncologist; 2010; 15(4):360-71. PubMed ID: 20413641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation protectants: current status and future prospects.
    Hayes DP
    Health Phys; 2006 Mar; 90(3):276; author reply 276-7. PubMed ID: 16505629
    [No Abstract]   [Full Text] [Related]  

  • 6. Radioprotective countermeasures for radiation injury (Review).
    Liu L; Liang Z; Ma S; Li L; Liu X
    Mol Med Rep; 2023 Mar; 27(3):. PubMed ID: 36799170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation countermeasure agents: an update.
    Dumont F; Le Roux A; Bischoff P
    Expert Opin Ther Pat; 2010 Jan; 20(1):73-101. PubMed ID: 20021286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models for radiation injury, protection and therapy.
    Augustine AD; Gondré-Lewis T; McBride W; Miller L; Pellmar TC; Rockwell S
    Radiat Res; 2005 Jul; 164(1):100-9. PubMed ID: 15966769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioprotective agents for radiation therapy: future trends.
    Johnke RM; Sattler JA; Allison RR
    Future Oncol; 2014 Dec; 10(15):2345-57. PubMed ID: 25525844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point: Should the ALARA Concept and Image Gently Campaign Be Terminated?
    Cohen MD
    J Am Coll Radiol; 2016 Oct; 13(10):1195-1198. PubMed ID: 27317375
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemical radiation protection of mammals and man].
    Mönig H
    Strahlenschutz Forsch Prax; 1985; 26():38-50. PubMed ID: 4089906
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of compounds that exhibit radioprotective and/or mitigatory effects after application of diagnostic or therapeutic ionizing radiation.
    Zivkovic Radojevic M; Milosavljevic N; Miladinovic TB; Janković S; Folic M
    Int J Radiat Biol; 2023; 99(4):594-603. PubMed ID: 35930681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of drugs in the prevention and amelioration of radiation induced toxic effects.
    Patyar RR; Patyar S
    Eur J Pharmacol; 2018 Jan; 819():207-216. PubMed ID: 29221951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials and radiation oncology technologies.
    Michalski JM; Bosch WR; Purdy JA
    Oncology (Williston Park); 2009 Apr; 23(4):386, 389. PubMed ID: 19476270
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute.
    Singh VK; Ducey EJ; Brown DS; Whitnall MH
    Int J Radiat Biol; 2012 Apr; 88(4):296-310. PubMed ID: 22191567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifostine as a radioprotectant.
    Gosselin TK; Mautner B
    Clin J Oncol Nurs; 2002; 6(3):175-6, 180. PubMed ID: 11998614
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating advanced technologies in radiation oncology: when and how should randomized trials be done?
    Sanguineti G; DeWeese TL
    Oncology (Williston Park); 2009 Apr; 23(4):390, 393. PubMed ID: 19476271
    [No Abstract]   [Full Text] [Related]  

  • 20. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.).
    Vordermark D; Guckenberger M; Baier K; Markert K
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):316-7. PubMed ID: 18406899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.